Breaking News
March 23, 2019 - The Current issue of “The view from here” is concerned with Cancer
March 23, 2019 - Mouse model validates how ‘good’ and ‘bad’ bacteria affect acne
March 23, 2019 - Individual amygdala neurons respond to touch, imagery and sounds
March 23, 2019 - Combination of two topical creams can prevent cancer
March 23, 2019 - Study suggests depression screening when assessing African-Americans for schizophrenia
March 23, 2019 - New electronic support system for choosing drug treatment based on patient’s genotype
March 23, 2019 - First-of-its-kind study provides pregnancy statistics of imprisoned U.S. women
March 23, 2019 - Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
March 23, 2019 - Laparoscopy: MedlinePlus Lab Test Information
March 23, 2019 - Shellfish allergies: can they be treated?
March 23, 2019 - Toilet seat heart monitoring system
March 23, 2019 - Researchers identify way to improve common treatment for PTSD
March 23, 2019 - High potency cannabis use linked to psychosis finds study
March 23, 2019 - Evoke Pharma Submits Response to FDA Review Letter for Gimoti NDA
March 23, 2019 - Tracking HIV’s ever-evolving genome in effort to prioritize public health resources
March 23, 2019 - Scientists grow most sophisticated brain organoid to date
March 23, 2019 - ADHD drug raising risk of psychosis
March 22, 2019 - FDA approves brexanolone, first drug developed to treat postpartum depression
March 22, 2019 - Gruesome cat and dog experiments by the USDA exposed
March 22, 2019 - Ball pits used in children’s physical therapy may contribute to germ transmission
March 22, 2019 - Long-term use of inexpensive weight-loss drug may be safe and effective
March 22, 2019 - FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
March 22, 2019 - Anti-Müllerian Hormone Test: MedlinePlus Lab Test Information
March 22, 2019 - Finding the right exercise, diet aids for HIV patients
March 22, 2019 - Health Plans For State Employees Use Medicare’s Hammer On Hospital Bills
March 22, 2019 - Researchers develop new tool for imaging large groups of neurons in living animals
March 22, 2019 - Certain bacteria and immune factors in vagina may cause or protect against preterm birth
March 22, 2019 - Novel breath test could pave new way to non-invasively measure gut health
March 22, 2019 - Pharmaceutical and personal care products may result in new contaminants in waterways
March 22, 2019 - ACC: Catheter Ablation Does Not Cut Mortality, Stroke in A-Fib
March 22, 2019 - Wiedemann-Rautenstrauch syndrome – Genetics Home Reference
March 22, 2019 - Health insurance is not assurance of healthcare
March 22, 2019 - Supporting “curiosity-driven research” at the Discovery Innovation Awards
March 22, 2019 - Must-Reads Of The Week (Some Flying Below The Radar)
March 22, 2019 - Newly engineered nanoscale protein micelles can be tracked by MRI
March 22, 2019 - New model more effective in predicting risk of opioid overdose than traditional models
March 22, 2019 - Mayo Clinic study identifies potential new drug therapy for liver diseases
March 22, 2019 - Pitt engineers win $550,000 NSF CAREER award to develop new intervention for people with ASD
March 22, 2019 - Early discharge does not increase readmission risk for patients after lung surgery
March 22, 2019 - Creating diverse pool of trained scientists to address Alzheimer’s research needs
March 22, 2019 - Surprising discovery offers clues to limit graft-vs.-host disease
March 22, 2019 - Study shows ACA’s positive impact on healthcare affordability and access for women
March 22, 2019 - Study provides new pathway for controlling inflammation
March 22, 2019 - New combination treatment shows promise for common brain tumor in children
March 22, 2019 - Virginia Tech Helmet Lab releases first youth-specific football helmet ratings
March 22, 2019 - New algae-based treatment could reduce need for limb amputation
March 22, 2019 - Stroke risk reduces in both black and white older Medicare beneficiaries, study reports
March 22, 2019 - City of Hope exhibits current studies and data on cancer therapies at AACR
March 22, 2019 - New study identifies CD40 molecule as key entry point for dangerous bacteria
March 22, 2019 - Health Tip: Six Steps to a Healthier Life
March 22, 2019 - even a little activity helps you live longer
March 22, 2019 - Many individuals recovering from addiction continue to suffer from chronic physical disease
March 22, 2019 - New drugs on PBS for Parkinson’s, MND and Cutaneous T cell lymphoma
March 22, 2019 - Saving energy also saves lives, UW-Madison study says
March 22, 2019 - Former inmates who receive social support have better mental health, study finds
March 22, 2019 - Nanofibrous membrane could enhance periodontal tissue regeneration
March 22, 2019 - Anti-vaxxer Italian leader down with chickenpox
March 22, 2019 - Servier collaborates with Harvard researchers to fight metabolic diseases
March 22, 2019 - National Eating Disorders Association
March 22, 2019 - Pumping up red blood cell production
March 22, 2019 - Excessive phosphate fertilizer may hurt plants by altering microbial composition in soil
March 22, 2019 - Medical marijuana laws could be improving older Americans’ health, study suggests
March 22, 2019 - Study indicates the benefits of stopping aspirin in heart attack patients
March 22, 2019 - Deep brain stimulation offers significant relief for patients with treatment-resistant depression
March 22, 2019 - Mental health problems in young adults on the rise
March 22, 2019 - Innovative membrane offers a viable solution for periodontitis
March 22, 2019 - The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI
March 22, 2019 - insulin therapy: MedlinePlus Medical Encyclopedia
March 22, 2019 - Guidelines on the use of genetic testing in psychiatry
March 22, 2019 - Aspiring Doctors Seek Advanced Training In Addiction Medicine
March 22, 2019 - A change in focus could enable the development of new treatments for Alzheimer’s disease
March 22, 2019 - A new way to visualize the immune cell “landscape” of bowel cancer tumors
March 22, 2019 - Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia
March 22, 2019 - Ludwig scientists to share advances in cancer research at AACR Annual Meeting 2019
March 22, 2019 - Less invasive valve replacement can be safe and effective alternative for healthier patients
March 22, 2019 - Aphasia research reveals new, complex interactions between thought and language
March 22, 2019 - Artificial neural networks can predict how different areas in the brain respond to words
March 22, 2019 - Age-related changes to gut microbiome have adverse impact on vascular health, study shows
March 22, 2019 - Study provides new insight into blood cell and immune cell production
March 22, 2019 - Isolated seniors chat online to prevent cognitive decline
Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

image_pdfDownload PDFimage_print

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company’s broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (GIST) as a proffered paper presentation at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich, Germany.

“We are extremely pleased with the preliminary results presented today that we believe demonstrate the potential of DCC-2618 to provide improved, durable clinical benefit for GIST patients from second-line through fourth-line-plus,” said Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera. “While the data set is still maturing, we believe the median progression free survival value of 42 weeks observed in second-line GIST patients strongly supports our planned randomized Phase 3 study, INTRIGUE, in second-line GIST patients, which we expect to initiate before the end of the year. In addition, the disease control rate and objective response rate observed with DCC-2618 in second-line GIST patients continues to exceed the values reported in previously published, centrally-read, registrational trials for sunitinib.”

The presentation reported preliminary results with a cutoff date of August 31, 2018 that include investigator-assessed median progression free survival (mPFS), objective response rates by best response (ORR) and disease control rates at 3 months (DCR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 across 178 patients receiving DCC-2618 at doses of ≥100mg daily:

Notes: (1) Includes nine unconfirmed responses: 2nd line (n=1), 3rd line (n=3) and ≥4th line (n=5); (2) Does not reflect one PR reported after cutoff date, which would result in an ORR in 2nd line of 21% and an ORR in 2nd line and 3rd line combined of 22%; (3) Excludes five patients due to missing data at the time of data cutoff (n=2), lack of first tumor assessment (n=1), withdrawal of consent prior to first assessment (n=1) and unrelated death at C1D4 prior to first assessment (n=1); (4) 59 of 67 combined 2nd line and 3rd line patients received 150mg once daily; and (5) Censored patients for mPFS were 2nd line (58%), 3rd line (52%), 4th line and 4th line plus (35%) and 2nd and 3rd line (55%).

“The preliminary progression free survival data and objective response rates observed with DCC-2618 are very encouraging across all lines of therapy presented: second-, third-, and fourth-line and beyond,” said Suzanne George, M.D., Director of Clinical Research, Center for Sarcoma and Bone Oncology and Senior Physician at the Dana Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. “There is a clear unmet need for effective and well tolerated options for patients with metastatic GIST beyond the first-line.”

Highlights from the proffered paper include:

Preliminary Clinical Activity in Second-, Third-, Fourth- and Fourth-Line-Plus GIST Patients Demonstrates the Potential for Durable Clinical Outcomes with DCC-2618

  • Progression Free Survival (mPFS): The mPFS values observed with DCC-2618 were 42 weeks in second-line patients and 40 weeks in third-line patients. Previously published results for approved therapies from centrally-read registrational trials reported a mPFS for sunitinib of 24 weeks in second-line patients and a mPFS for regorafenib of 21 weeks in third-line patients. In fourth- and fourth-line-plus patients, where there are currently no approved therapies, the observed mPFS with DCC-2618 was 24 weeks. Published studies have reported a mPFS of 4-6 weeks for similarly heavily pre-treated patients who did not receive an active therapy.
  • Disease Control Rate (DCR): The observed DCRs at three months of 79% in second-line patients and 83% in third-line patients exceed the previously published results for approved therapies from centrally-read registrational trials of 60% for sunitinib in second-line patients and 53% for regorafenib in third-line patients. The DCR observed for DCC-2618 in fourth-line and fourth-line-plus patients was 66%.
  • Objective Response Rate (ORR): The observed ORRs of 18% in second-line patients and 24% in third-line patients continue to exceed the previously published results for approved therapies from centrally-read registrational trials of 7% for sunitinib in second-line patients and 5% for regorafenib in third-line patients. These values do not include a partial response in one second-line patient that was observed after the cutoff date, which would result in an ORR in second-line patients of 21%. The ORR observed for DCC-2618 in fourth-line and fourth-line-plus patients was 9%.

Prolonged Treatment Duration in GIST Patients Receiving DCC-2618 – Cutoff Date of August 31, 2018

  • In the second-line cohort, as of the cutoff date, 17 patients received DCC-2618 at doses of 100mg daily for >6 months with 65% (11 of 17) of these patients remaining on study.
  • In the third-line cohort, as of the cutoff date, 20 patients received DCC-2618 at doses of 100mg daily for >6 months with 75% (15 of 20) of these patients remaining on study.
  • In the fourth-line and fourth-line-plus patients, as of the cutoff date, 46 patients received DCC-2618 at doses of 100mg daily for >6 months with 74% (34 of 46) of these patients remaining on study.

Updated Safety Data Continue to Demonstrate a Favorable Tolerability Profile for DCC-2618

  • For 178 GIST patients treated at doses above ≥100mg daily, DCC-2618 was generally well tolerated.
  • Among the treatment-emergent adverse events (TEAEs) reported by investigators (>10%), regardless of relationship to DCC-2618, the most common were: alopecia (50%), myalgia (44%), fatigue (43%), constipation (34%), hand-foot skin reaction (32%), nausea (30%), decreased appetite (28%), weight decreased (24%), abdominal pain (23%), diarrhea (23%) and lipase increase (23%).
  • Among the 178 GIST patients treated at doses above ≥100mg daily:
  • 14% (24) patients experienced dose reductions due to TEAE.
  • 11% (19) experienced treatment discontinuations due to TEAE.

Source:

https://investors.deciphera.com/node/7256

Tagged with:

About author

Related Articles